Movement Alert|CVS Health Intraday Rise 3.03% in Regular Trading, shares rebound as analysts keep broadly positive targets after earnings and breakup update

Market Focus11-11

On November 11, CVS Health rose 3.03% in Regular Trading, trading at $87.875 per share, with turnover of $523 million.

The latest visible catalyst was a new analyst target-price revision: Argus lowered its price target to $105 from $114 while the stock continued to carry an average buy rating, with the mean analyst target around $110.38. That followed Barclays trimming its target to $107 from $108 days earlier, suggesting a more cautious valuation stance but not a broad downgrade in Street sentiment.

Recent fundamentals remain supportive. CVS Health reported third-quarter adjusted EPS of $2.09 on revenue of $108.399 billion, both above consensus, and guided to full-year adjusted EPS of at least $8.20 versus market expectations near $8.05. The company also said it plans to separate its retail pharmacy business from its insurance and pharmacy-benefit operations into two publicly traded companies in the first half of 2028, a move that has prompted investors to reassess valuation despite mixed initial market reaction.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment